XML 80 R65.htm IDEA: XBRL DOCUMENT
v3.24.0.1

License and Collaboration Agreements - Additional Information (Detail) |  |  | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | ---
Nov. 30, 2020 USD ($) | Oct. 27, 2020 USD ($) | Jan. 31, 2024 USD ($) | Nov. 30, 2023 USD ($) | Oct. 31, 2023 USD ($) | Apr. 30, 2023 USD ($) | Jan. 31, 2023 USD ($) | Jun. 30, 2022 USD ($) | Apr. 30, 2022 USD ($) | Jan. 31, 2022 USD ($) | Aug. 31, 2021 USD ($) | Jun. 30, 2021 Program | Jan. 31, 2021 USD ($) | Dec. 31, 2023 USD ($) License | Dec. 31, 2022 USD ($) | Dec. 31, 2020 USD ($) | Jul. 31, 2021 USD ($) | Oct. 31, 2020 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalties receivable |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,054,000 | $ 1,442,000 |  |  |
Accrued expenses |  |  |  |  |  |  |  |  |  |  |  |  |  | 127,806,000 | 95,139,000 |  |  |
Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development cost reimbursement received |  |  | $ 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
SYFOVRE [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty expense incurred |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,900,000 |  |  |  |
Regulatory milestone payments |  |  |  | $ 2,000,000 |  | $ 2,300,000 |  |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone incurred |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000 |  |  |  |
Regulatory milestone accrued |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,000,000 |  |  |  |
Empaveli And Aspaveli [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty expense incurred |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,900,000 |  |  |  |
Accrued expenses |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,500,000 |  |  |  |
Swedish Orphan Biovitrum AB (Publ) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development cost reimbursement |  | $ 80,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable Upfront Payment |  | 250,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |
Collaboration and License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development cost reimbursement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 80,000,000 |  |
Collaboration and License Agreement [Member] | License [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 250,000,000 |  |
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ 250,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment received for achievement of regulatory development milestone |  |  |  |  | $ 5,000,000 |  |  |  | $ 50,000,000 |  |  |  |  |  |  |  |  |
Development cost reimbursement |  |  |  |  |  |  |  |  |  |  |  |  | $ 80,000,000 |  |  |  |  |
Development cost reimbursement received |  |  |  |  |  |  | $ 20,000,000 |  |  | $ 20,000,000 |  |  | 25,000,000 |  |  |  |  |
Royalties entitled to receive after first commercial sale of applicable licensed product period |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |  |  |  |
Royalty revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,000,000 |  |  |
Royalties received |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |
Contract research and development expense |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 5,000,000 |  |  |
Remaining reimbursement payment |  |  | 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract research and development reimbursement commitment |  | 80,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract research and development current |  |  |  |  |  |  |  |  |  |  |  |  |  | 15,000,000 |  |  |  |
Contract research and development receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 35,000,000 |  |  |
Contract research and development receivable other current assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,000,000 |  |  |
Contract research and development receivable other assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000,000 |  |  |
Proceeds from contract research and development |  |  |  |  |  |  | 20,000,000 |  |  |  |  |  |  |  |  |  |  |
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining reimbursement payment |  |  | $ 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member] | ASC Topic 808 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ 250,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development cost reimbursement |  | 80,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate milestone payments upon achievement of specified one time regulatory development and commercial milestone events |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 915,000,000
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member] | Maximum [Member] | ASC Topic 808 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate milestone payments upon achievement of specified one-time regulatory and commercial milestone events |  | $ 915,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
University of Pennsylvania [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual maintenance fees |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 |  |  |  |
Development milestone achievement |  |  |  |  |  |  |  | $ 5,000,000 |  |  | $ 1,000,000.0 |  |  |  |  |  |  |
University of Pennsylvania [Member] | Empaveli And Aspaveli [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments based on annual sales milestones |  |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |
University of Pennsylvania [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate milestones payments |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,200,000 |  |  |  |
Milestone payments based on annual sales milestones |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000.0 |  |  |  |
2010 License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual maintenance fees |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 100,000 |  |  |  |
Number of licensed products | License |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |
2010 License Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate milestones payments |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,700,000 |  |  |  |
Milestone payments based on annual sales milestones |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,500,000 |  |  |  |
Sobi Agreement and Another Licensing Transaction [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sublicense fee owed |  |  |  |  |  |  |  |  |  |  |  |  | $ 25,000,000.0 | $ 500,000 |  |  |  |
Research Collaboration Agreement [Member] | Beam [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement term |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |
Number of research programs | Program |  |  |  |  |  |  |  |  |  |  |  | 6 |  |  |  |  |  |
Up-front non-refundable payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000,000 |
Up-front payment on first anniversary of agreement on June 30, 2022 |  |  |  |  |  |  |  | $ 25,000,000 |  |  |  |  |  |  |  |  |  |
Collaboration agreement maximum extendable term |  |  |  |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |  |

X
- Definition Aggregate milestone payments upon achievement of specified one-time regulatory and commercial milestone events. + References No definition available. + Details
Name: | apls_AggregateMilestonePaymentsUponAchievementOfSpecifiedOneTimeRegulatoryAndCommercialMilestoneEvents
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate milestone payments upon achievement of specified one time regulatory development and commercial milestone events. + References No definition available. + Details
Name: | apls_AggregateMilestonePaymentsUponAchievementOfSpecifiedOneTimeRegulatoryDevelopmentAndCommercialMilestoneEvents
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Annual license maintenance fees. + References No definition available. + Details
Name: | apls_AnnualLicenseMaintenanceFees
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative arrangement, maximum extendable term of agreement. + References No definition available. + Details
Name: | apls_CollaborativeArrangementMaximumExtendableTermOfAgreement
Namespace Prefix: | apls_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement, number of research programs. + References No definition available. + Details
Name: | apls_CollaborativeArrangementNumberOfResearchPrograms
Namespace Prefix: | apls_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement, term of agreement. + References No definition available. + Details
Name: | apls_CollaborativeArrangementTermOfAgreement
Namespace Prefix: | apls_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement, up-front payment in next twelve months. + References No definition available. + Details
Name: | apls_CollaborativeArrangementUpFrontPaymentInNextTwelveMonths
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative arrangement upfront non-refundable amount payable. + References No definition available. + Details
Name: | apls_CollaborativeArrangementUpfrontNonRefundableAmountPayable
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contra research and development expense. + References No definition available. + Details
Name: | apls_ContraResearchAndDevelopmentExpense
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contract research and development current. + References No definition available. + Details
Name: | apls_ContractResearchAndDevelopmentCurrent
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contract research and development other assets. + References No definition available. + Details
Name: | apls_ContractResearchAndDevelopmentOtherAssets
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contract research and development other current assets. + References No definition available. + Details
Name: | apls_ContractResearchAndDevelopmentOtherCurrentAssets
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contract research and development receivable. + References No definition available. + Details
Name: | apls_ContractResearchAndDevelopmentReceivable
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contract research and development reimbursement commitment. + References No definition available. + Details
Name: | apls_ContractResearchAndDevelopmentReimbursementCommitment
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development cost reimbursement. + References No definition available. + Details
Name: | apls_DevelopmentCostReimbursement
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development cost reimbursement received. + References No definition available. + Details
Name: | apls_DevelopmentCostReimbursementReceived
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development milestone achievement. + References No definition available. + Details
Name: | apls_DevelopmentMilestoneAchievement
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment received for achievement of regulatory development milestone. + References No definition available. + Details
Name: | apls_MilestonePaymentReceivedForAchievementOfRegulatoryDevelopmentMilestone
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition non-refundable upfront payment. + References No definition available. + Details
Name: | apls_NonRefundableUpfrontPayment
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of licensed products. + References No definition available. + Details
Name: | apls_NumberOfLicensedProducts
Namespace Prefix: | apls_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Proceeds from contract research and development . + References No definition available. + Details
Name: | apls_ProceedsFromContractResearchAndDevelopment
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Regulatory milestone accrued based on achievement. + References No definition available. + Details
Name: | apls_RegulatoryMilestoneAccruedBasedOnAchievement
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Regulatory milestone incurred based on achievement. + References No definition available. + Details
Name: | apls_RegulatoryMilestoneIncurredBasedOnAchievement
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Regulatory milestone payments based on achievement. + References No definition available. + Details
Name: | apls_RegulatoryMilestonePaymentsBasedOnAchievement
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Remaining reimbursement payment. + References No definition available. + Details
Name: | apls_RemainingReimbursementPayment
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Royalties entitled to receive after first commercial sale of applicable licensed product period. + References No definition available. + Details
Name: | apls_RoyaltiesEntitledToReceiveAfterFirstCommercialSaleOfApplicableLicensedProductPeriod
Namespace Prefix: | apls_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalties receivable current. + References No definition available. + Details
Name: | apls_RoyaltiesReceivableCurrent
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Royalty expense incurred. + References No definition available. + Details
Name: | apls_RoyaltyExpenseIncurred
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Royalty revenue. + References No definition available. + Details
Name: | apls_RoyaltyRevenue
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sales milestone payments based on achievement of annual sales milestones. + References No definition available. + Details
Name: | apls_SalesMilestonePaymentsBasedOnAchievementOfAnnualSalesMilestones
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sublicense fee owed. + References No definition available. + Details
Name: | apls_SublicenseFeeOwed
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront payment. + References No definition available. + Details
Name: | apls_UpfrontPayment
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a),(c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_ProceedsFromRoyaltiesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=apls_SyfovreMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=apls_EmpaveliAndAspaveliMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=apls_SwedishOrphanBiovitrumABPublMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_UniversityOfPennsylvaniaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_TwoThousandTenLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_SobiAgreementAndAnotherLicensingTransactionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_ResearchCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=apls_BeamTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |